Brief Report: Long-Term (96-Week) Efficacy and Safety after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

François Raffi, Chloe Orkin, Amanda Clarke, Laurence Slama, Joel Gallant, Eric Daar, Keith Henry, Jorge Santana-Bagur, David K. Stein, Nicholaos Bellos, Anthony Scarsella, Mingjin Yan, Michael E. Abram, Andrew Cheng, Martin S. Rhee

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs. remain on tenofovir disoproxil fumarate (TDF; n = 330), each coformulated with emtricitabine (FTC), while continuing their third agent (boosted protease inhibitor or unboosted third agent). At week 96, 88.6% on FTC/TAF and 89.1% on FTC/TDF had HIV-1 RNA <50 copies per milliliter [adjusted difference -0.5% (95% confidence interval: -5.3 to 4.4%)]. Proteinuria, albuminuria, proximal renal tubular function, and bone mineral density improved after switching to TAF- from TDF-containing regimens. These longer-term data support FTC/TAF as a safe, well-tolerated, and durable nucleotide reverse transcriptase inhibitor backbone.

Original languageEnglish (US)
Pages (from-to)226-231
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume75
Issue number2
DOIs
StatePublished - Jun 1 2017

Bibliographical note

Publisher Copyright:
© 2017 The Author(s). Published by Wolters Kluwer Health, Inc.

Keywords

  • HIV
  • osteopenia
  • proteinuria
  • tenofovir alafenamide

Fingerprint Dive into the research topics of 'Brief Report: Long-Term (96-Week) Efficacy and Safety after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults'. Together they form a unique fingerprint.

Cite this